Skip to main content
Erschienen in: Digestive Diseases and Sciences 6/2022

16.04.2022 | Stanford Multidisciplinary Seminars

Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC)

verfasst von: Damien Bouriez, Caroline Gronnier, Haythem Najah, Denis Collet

Erschienen in: Digestive Diseases and Sciences | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Excerpt

A 61-year-old man was seen in the gastroenterology outpatient clinic due to recurrent heartburn. Five years prior, he had experienced gastroesophageal acid reflux symptoms that were treated with proton pump inhibitors for 4 months. Since that first episode, he had neither clinical follow-up nor endoscopic evaluation. At presentation, he described moderate dysphagia but he had not lost weight, weighing 94 kg. Upper gastrointestinal endoscopy demonstrated an esophageal tumor, extending 35–42 cm from the incisors from the distal esophagus, without stenosis, to the lesser curvature of the stomach. Mucosal biopsies demonstrated adenocarcinoma with poorly cohesive cells (PCC), conferring a poor prognosis. Preoperative evaluation, included a thoraco-abdominal CT scan (Fig. 1) and a PET scan (Fig. 2) concluded that the patient had a large gastroesophageal junctional tumor classified as Siewert I-II-III extending from the lower esophagus to the lesser curvature of the stomach (Fig. 3). A pretherapeutic laparoscopy did not show any peritoneal metastases. Perioperative chemotherapy was given according to the FLOT regimen: fluorouracil, leucovorin, oxaliplatin, and docetaxel [1]. The patient did not experience any toxicity. A re-evaluation by CT scan performed 2 weeks after the end of the chemotherapy demonstrated tumor stability without progression.
Literatur
1.
Zurück zum Zitat Mariette C, Carneiro F, Grabsch HI et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRef Mariette C, Carneiro F, Grabsch HI et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22:1–9.CrossRef
2.
Zurück zum Zitat Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–887.CrossRef Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250:878–887.CrossRef
3.
Zurück zum Zitat Gronnier C, Messager M, Robb WB et al. Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma? Surgery. 2013;154:1093–1099.CrossRef Gronnier C, Messager M, Robb WB et al. Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma? Surgery. 2013;154:1093–1099.CrossRef
4.
Zurück zum Zitat Dupas J-L. COMITE D’ORGANISATION. 2001;7. Dupas J-L. COMITE D’ORGANISATION. 2001;7.
5.
Zurück zum Zitat Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74–94.CrossRef Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74–94.CrossRef
6.
Zurück zum Zitat Dumonceau J-M, Deprez PH, Jenssen C et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. Endoscopy. 2017;49:695–714.CrossRef Dumonceau J-M, Deprez PH, Jenssen C et al. Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. Endoscopy. 2017;49:695–714.CrossRef
7.
Zurück zum Zitat Ahn HS, Lee H-J, Yoo M-W et al. Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer. J Surg Oncol. 2009;99:20–27.CrossRef Ahn HS, Lee H-J, Yoo M-W et al. Diagnostic accuracy of T and N stages with endoscopy, stomach protocol CT, and endoscopic ultrasonography in early gastric cancer. J Surg Oncol. 2009;99:20–27.CrossRef
8.
Zurück zum Zitat Honoré C, Goéré D, Messager M et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: Results of a multicentre retrospective study. Eur J Surg Oncol. 2013;39:235–241.CrossRef Honoré C, Goéré D, Messager M et al. Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: Results of a multicentre retrospective study. Eur J Surg Oncol. 2013;39:235–241.CrossRef
9.
Zurück zum Zitat van der Kaaij RT, Snaebjornsson P, Voncken FEM et al. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. Eur J Cancer. 2017;76:27–35.CrossRef van der Kaaij RT, Snaebjornsson P, Voncken FEM et al. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. Eur J Cancer. 2017;76:27–35.CrossRef
10.
Zurück zum Zitat Raziee HR, Cardoso R, Seevaratnam R et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2012;15:S116-124.CrossRef Raziee HR, Cardoso R, Seevaratnam R et al. Systematic review of the predictors of positive margins in gastric cancer surgery and the effect on survival. Gastric Cancer. 2012;15:S116-124.CrossRef
11.
Zurück zum Zitat Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–2668.CrossRef Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–2668.CrossRef
12.
Zurück zum Zitat Marrelli D, Polom K, Pascale V et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann Surg Oncol. 2016;23:943–950.CrossRef Marrelli D, Polom K, Pascale V et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann Surg Oncol. 2016;23:943–950.CrossRef
13.
Zurück zum Zitat Al-Batran S-E, Hofheinz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–1708.CrossRef Al-Batran S-E, Hofheinz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–1708.CrossRef
14.
Zurück zum Zitat Wang K, Li E, Busuttil RA et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol. 2020;12:1758835920930359.PubMedPubMedCentral Wang K, Li E, Busuttil RA et al. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol. 2020;12:1758835920930359.PubMedPubMedCentral
15.
Zurück zum Zitat Heger U, Blank S, Wiecha C et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739–1748.CrossRef Heger U, Blank S, Wiecha C et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739–1748.CrossRef
16.
Zurück zum Zitat Kelly RJ, Ajani JA, Kuzdzal J et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–1203.CrossRef Kelly RJ, Ajani JA, Kuzdzal J et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–1203.CrossRef
17.
Zurück zum Zitat Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717–726.CrossRef Muro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717–726.CrossRef
18.
Zurück zum Zitat Kang Y-K, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.CrossRef Kang Y-K, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471.CrossRef
19.
Zurück zum Zitat Berlth F, Kim W-H, Choi J-H et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg. 2020;272:871–878.CrossRef Berlth F, Kim W-H, Choi J-H et al. Prognostic impact of frozen section investigation and extent of proximal safety margin in gastric cancer resection. Ann Surg. 2020;272:871–878.CrossRef
21.
Zurück zum Zitat Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38-49.CrossRef Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38-49.CrossRef
22.
Zurück zum Zitat Spicer J, Benay C, Lee L et al. Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma. Ann Surg Oncol. 2014;21:2580–2586.CrossRef Spicer J, Benay C, Lee L et al. Diagnostic accuracy and utility of intraoperative microscopic margin analysis of gastric and esophageal adenocarcinoma. Ann Surg Oncol. 2014;21:2580–2586.CrossRef
23.
Zurück zum Zitat Reslinger V, Tranchart H, D’Annunzio E et al. Esophageal reconstruction by colon interposition after esophagectomy for cancer analysis of current indications, operative outcomes, and long-term survival. J Surg Oncol. 2016;113:159–164.CrossRef Reslinger V, Tranchart H, D’Annunzio E et al. Esophageal reconstruction by colon interposition after esophagectomy for cancer analysis of current indications, operative outcomes, and long-term survival. J Surg Oncol. 2016;113:159–164.CrossRef
24.
Zurück zum Zitat Bilosi M, Bernard A, Favre JP et al. Coloplasty after esophagectomy in cancer. A retrospective study of morbidity and mortality. Ann Chir. 1999;53:854–8.PubMed Bilosi M, Bernard A, Favre JP et al. Coloplasty after esophagectomy in cancer. A retrospective study of morbidity and mortality. Ann Chir. 1999;53:854–8.PubMed
26.
Zurück zum Zitat Coevoet D, Van Daele E, Willaert W et al. Quality of life of patients with a colonic interposition postoesophagectomy. Eur J Cardiothorac Surg. 2019;55:1113–1120.CrossRef Coevoet D, Van Daele E, Willaert W et al. Quality of life of patients with a colonic interposition postoesophagectomy. Eur J Cardiothorac Surg. 2019;55:1113–1120.CrossRef
27.
Zurück zum Zitat Cense HA, Visser MRM, van Sandick JW et al. Quality of life after colon interposition by necessity for esophageal cancer replacement. J Surg Oncol. 2004;88:32–38.CrossRef Cense HA, Visser MRM, van Sandick JW et al. Quality of life after colon interposition by necessity for esophageal cancer replacement. J Surg Oncol. 2004;88:32–38.CrossRef
Metadaten
Titel
Making It Stick: Management of Gastroesophageal Junction Adenocarcinoma with Poorly-Cohesive Cells (PCC)
verfasst von
Damien Bouriez
Caroline Gronnier
Haythem Najah
Denis Collet
Publikationsdatum
16.04.2022
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 6/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07437-4

Weitere Artikel der Ausgabe 6/2022

Digestive Diseases and Sciences 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.